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Abstract
When used in overdoses, acetaminophen (APAP) is a common cause of morbidity and mortality in humans. At pre-
sent, N-acetylcysteine (NAC) is the antidote of choice for acetaminophen overdoses. Prompt administration of NAC
can prevent the deleterious actions of APAP in the liver. In view of the similarities in antioxidant effects demon-
strated by NAC, hypotaurine (HYTAU) and taurine (TAU) in this and other our laboratories, the present study was
undertaken to compare these compounds for the ability to attenuate plasma and liver biochemical changes asso-
ciated with a toxic dose of APAP. For this purpose, fasted male Sprague-Dawley rats, 225-250 g in weight, were
intraperitoneally treated with APAP (800 mg/kg), NAC, HYTAU or TAU (2.4 mM/kg) followed 30 min later by APAP,
or 50% PEG 400 (the vehicle for APAP). At 6 hr after APAP administration, all animals were sacrificed by decapita-
tion and their blood and livers collected. The plasma fractions were analyzed for indices of liver damage (alanine
transaminase, aspartate transaminase, lactate dehydrogenase), levels of malondialdehyde (MDA), reduced (GSH) and
oxidized (GSSG) glutathione, and activities of glutathione reductase (GR), glutathione S-transferase (GST) and g-glu-
tamylcisteinyl synthetase (GCS). Suitable liver homogenates were analyzed for the same biochemical parameters as
the plasma but indices of liver damage. By itself, APAP increased MDA formation and had a significant lowering
influence on the levels of GSH and GSSG, the GSH/GSSH ratio, and the activities of GR, GST and GCS both in the
plasma and liver. In addition, APAP promoted the leakage of transaminases and lactate dehydrogenase from the
liver into the plasma. Without exceptions, a pretreatment with a sulfur-containing compound led to a significant
attenuation of the liver injury and the biochemical changes induced by APAP. Within a narrow range of potency
differences, HYTAU appeared to be the most protective and TAU the least. The present results suggest that, irre-
spective of the differences in structural features and in vitro antioxidant properties that may exist among NAC, TAU
and HYTAU, these compounds demonstrate equivalent patterns of protection and, to a certain extent, equipotent
protective actions against the toxic actions of APAP in the liver when tested in equimolar doses and under the
same conditions in an animal model.
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Background
Therapeutic doses of the analgesic drug acetaminophen
(APAP) are readily detoxified by hepatic phase II drug-
metabolizing systems mediating glucuronidation and sul-
fation [1], with a small portion undergoing a cytochrome
P-450-mediated bioactivation to the highly reactive elec-
trophilic arylating intermediate N-acetyl-p-benzoquino-
neimine (NAPQI) [2]. In rats and humans, NAPQI is
detoxified principally by conjugation with reduced
glutathione (GSH) under spontaneous or glutathione S-
transferase (GST)-mediated conditions to the 3-glu-
tathione-S-yl-APAP conjugate [1].
In the event of the intake of an overdose of APAP, the
increased production of NAPQI rapidly overwhelms
GST, eventually exhausts GSH, UDP-glucuronic acid
and inorganic sulfate [3], inhibits GSH synthesis [3,4]
and decreases cytosolic GST activity [5]. More impor-
tantly, this APAP metabolite is a major cause of hepato-
cellular damage, centrilobular hepatic necrosis and even
fatalities upon entering in adduct formation with liver
macromolecules, especially proteins [6].
The hepatotoxicity of APAP is generally recognized to
start with the formation of NAPQI and to be related to
the oxidative stress that develops as a result of the oxi-
dative capacities of this reactive metabolic product
[6-10]. NAPQI is capable of lowering GSH/GSSG ratio
by oxidizing the thiol group of GSH and of promoting
the formation of interstrand disulfide linkages, interpro-
tein cross links and protein-GSH mixed disulfides by
oxidizing cysteine thiol groups in proteins [10]. APAP
may also cause hepatotoxicity by mechanisms leading to
the formation of reactive oxygen species (ROS), such as
superoxide anion (O2
-•), hydrogen peroxide (H2O2) and
hydroxyl radical (HO•), reactive nitrogen species (RNS),
such as nitric oxide and peroxynitrite (ONOO-), and
peroxidation reaction products [6-8,10].
Furthermore, the APAP-associated depletion of the
intrahepatic GSH is accompanied by variable alterations
in glutathione disulfide (GSSG) contents [11,12] and by
reductions in the activities of the antioxidant enzymes
glutathione reductase (GR) [13,14], g-glutamylcysteinyl
synthetase (GCS), catalase (CAT), glutathione peroxi-
dase (GPX) and superoxide dismutase (SOD) [14].
Since NAPQI formation, GSH depletion, and the alky-
lation of proteins, especially in the mitochondrion, are
central to the onset of hepatotoxicity by APAP [15],
compounds with potential for serving as a source of
GSH [3,16-19] or for preventing oxidative reactions
[19-24] have been extensively studied for the ability to
counteract APAP toxicity. Based on this evidence, the
present study was aimed at comparing the hepatopro-
tective actions of taurine (TAU), a nonprotein sulfur-
containing amino acid, and hypotaurine (HYTAU), the
immediate metabolic precursor of TAU, with that of
N-acetyl-L-cysteine (NAC), an L-cysteine analog that
can serve as a substrate for GSH synthesis [16,18,25].
While NAC is regarded as the antidote of choice for
APAP overdoses [18] and as an effective antioxidant
[26-28], information on the protective actions of TAU
in APA-induced acute liver injury appears to be limited
to a report indicating that this amino acid can attenuate
the leakage of intracellular enzymes from and DNA
fragmentation, lipid peroxidation (LPO), apoptosis and
necrosis in the hepatocytes of rats receiving a toxic dose
of APAP [29]. On the other hand, earlier work from this
laboratory has determined that both TAU) and HYTAU
can attenuate LPO, preserve the intracellular stores of
GSH, and prevent the losses of antioxidant enzyme
activities in erythrocytes of rats exposed to an oxidant
[30] or affected by type 2 diabetes [31]. In addition, the
results of in vitro experiments with free radical generat-
ing systems have suggested that HYTAU, because of its
sulfinate functionality, is a better antioxidant and radical
scavenger than TAU [32]. The purpose of the present
study was to compare NAC, HYTAU and TAU for their
effects in preventing oxidative stress and, thus, liver
injury, when administered in equimolar doses to rats
and as a pretreatment to a toxic dose of APAP.
Methods
Animals
Male Sprague-Dawley rats, 225-250 g in weight, were pur-
chased from Taconic Farms, Germantown, New York,
USA, and housed in a temperature controlled room (21
±1°C) with a 12 hr light-12 hr dark cycle; and allowed free
access to a standard rat chow and filtered tap water for at
least 5 days. The solid food, but not the water, was
removed 12 hr prior to an experiment. The study received
the approval of the Institutional Animal Care and Use
Committee of St. John’s University, and the animals were
cared for in accordance with the guidelines established by
the United States Department of Agriculture.
Treatments and samples
The treatment solutions were prepared either in warm
50% PEG 400 (APAP) or in distilled water (NAC, TAU,
HYTAU). All the solutions were administered by the
intraperitoneal (i.p.) route. A treatment compound was
administered as a single, 2.4 mM/kg/2 mL dose, 30 min
before APAP (800 mg/kg/2 mL). Control animals
received only 50% PEG 400 or only a sulfur-containing
compound. The animals were sacrificed by decapitation
at 6 hr post-APAP, and their blood samples were
promptly delivered into heparinized test tubes for subse-
quent centrifugation and processing for the plasma frac-
tion. Following surgery of the animals, the livers were
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exposed and immediately freeze-clamped with metal
tongs precooled in liquid nitrogen, and stored in liquid
nitrogen until needed.
Liver homogenates
A liver homogenate for the assay of GSH and GSSG was
prepared by mixing a portion of liver sample with 4
times its volume of 25% metaphosphoric acid plus 14
times its volume of PBS pH 8.0, followed by homogeni-
zation on ice with the help of a hand held electric blen-
der. The suspension was centrifuged at 5,000 rpm and
4oC for 5 min, and the resulting supernatant was stored
on ice until needed. For the remaining assays, a liver
homogenate was prepared by mixing one part of liver
sample with 20 times its volume of 0.01% phenylmethyl-
sulfonyl fluoride in Tris buffer pH 7.0 followed by
homogenization with a hand held electric blender while
on an ice bath. The suspension was centrifuged at
12,000 rpm and 4°C for 30 min, and the resulting super-
natant was stored on ice until needed
Assay of MDA
The concentration of MDA in the liver and plasma was
measured as TBARS using a published colorimetric
method [33]. To this effect, an aliquot of liver homoge-
nate (or of plasma) was mixed with a reagent consisting
of 15% TCA (w/v)-0.375% TBA (w/v)-0.25 N HCl in a
1:9 ratio (by volume), and heated at 90oC for 1 hr. After
allowing it to cool to room temperature, the mixture
was centrifuged at 2000 x g for 5 min to remove insolu-
bles, and its absorbance read at 535 nm on a spectro-
photometer. The level of MDA was derived from a
standard curve prepared from serial dilutions of a stock
solution of TEP that were treated in an identical manner
as the liver samples. The concentration of MDA was
expressed as nmol/mg of protein.
Assay of GSH and GSSG
The concentrations of GSH and GSSG in a liver sample
were measured by a fluorometric method that uses OPT
as a fluorescent reagent [34]. The method takes advan-
tage of the reaction of GSH with OPT at pH 8 and of
GSSG with OPT at pH 12. An aliquot of liver homoge-
nate in 25% metaphosphoric acid (or plasma) was mixed
with 9 times its volume of 10 mM phosphate buffer pH
8.0, and an aliquot of this mixture was treated with an
equal volume OPT solution (1 mg/ml). After standing at
ambient temperature for 15 min, the fluorescence of the
solution was measured on a fluorometer set at an emis-
sion wavelength of 420 nm and an excitation wavelength
of 350 nm. For the assay of GSSG, an aliquot of liver
homogenate in 25% metaphosphoric acid (or plasma)
was mixed with 0.04 M NEM in a 10:4 ratio. After 30
min, the sample was diluted with 0.1 N sodium
hydroxide in a ratio of 1:6, and an aliquot of this dilution
was treated with an equal volume of OPT. The fluores-
cence of the dilution was read on a fluorometer as
described for GSH. The concentrations of GSH and
GSSG in the sample were derived by reference to calibra-
tion curves of GSH and GSSG prepared from serial dilu-
tions of GSH and GSSG stock solutions that were treated
in an identical manner as the lung homogenate or plasma
sample. The results were reported as µM/g of tissue in
the case of liver samples and as µg/ml in the case of
plasma samples.
Assay of GR activity
The GR activity was measured based on the rate of oxi-
dation of NADPH to NADP+, a process that is accompa-
nied by a decrease in absorbance at 340 nm [35].
A reaction mixture for this assay was prepared by dilut-
ing a portion of liver homogenate with 10 mM phosphate
buffer pH 7.4 in a 1:10 ratio, adding 50 µl of 20 mM
GSSG, and incubating the mixture at 37°C for 3 min.
The reaction was started by adding 50 µl of 1.5 mM
NADPH in 01% sodium bicarbonate, and monitoring the
consumption of NADPH at 340 nm for 5 min. The activ-
ity of GR was calculated using an extinction coefficient
for NADPH of 6.22 mM-1•cm-1 and was expressed as µM
of NADPH consumed/min/mg of protein.
Assay of GCS activity
The GCS activity was measured by a spectrophotometric
method in which the rate of formation of ADP gener-
ated in the GCS-catalyzed reaction was measured by
coupling it to LDH-PK system [36]. The assay medium
consisted of 100 µl 100 M Tris-HCl buffer pH 8.2, 100
µl 200 mM magnesium chloride, 100 µl 1.5 M potas-
sium chloride, 100 µl L-glutamic acid, 100 µl 100 mM
L-cysteine, 50 µl 100 mM ATP, 133 µl 1.5 mM NADH,
100 µl 20 mM phosphoenolpyruvate, 50 µl 40 U/ml PK
and 2 µl 1KU/ml LDH. After initiating the reaction by
the addition of 100 µl of sample (plasma or liver homo-
genate) and incubating at 37°C for 3-4 min, the change
in absorbance at 340 nm, due to the oxidation of
NADH, was monitored for 1 min. The GCS activity of
the sample was expressed in U/min/mg of protein,
where one unit is defined as the amount of enzyme cat-
alyzing the consumption of 1 µM of NADH/min/mg of
protein under the assay conditions used.
Assay of GST activity
The assay of the GST activity was based upon the GST-
catalyzed reaction between GSH and CDNB, a GST sub-
strate, to produce a colored dinitrophenyl thioether that
can be measured on a spectrophotometer set at 340 nm
[37]. The reaction mixture contained 100 µl of liver homo-
genate (or plasma sample), 1.7 ml of phosphate buffer pH
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7.4, 100 µl of 20 mM GSH, and 100 µl of 20 mM CDNB.
The rate of formation of a CDNB-GSH conjugate at 25°C
was monitored on a spectrophotometer at 340 nm for 5
min. The GST activity, defined as the amount of enzyme
producing 1 µmol of CDNB-GSH conjugate/min under
the conditions of the assay, was calculated using an extinc-
tion coefficient for CDNB of 9.6 mM-1•cm-1. The results
were expressed in U/min/mg of protein.
Statistical analysis
The experimental results are expressed as mean ± stan-
dard error of the mean (SEM) for n = 6. Differences
between the control and the various treatment groups
were determined by Student’s t-test followed by one-way
analysis of variance (ANOVA) and Newman-Keuls mul-
tiple-range test. A p value <0.05 was taken as an indica-
tion of a statistically significant difference.
Results
The effect of APAP, alone and in combination with a
sulfur-containing compound, on enzymatic indices of
hepatocellular damage
The occurrence of hepatocellular damage induced by a
toxic (800 mg/kg) dose of APAP and the influence of a
pretreatment with a sulfur-containing compound was
investigated by measuring the leakage of hepatic ALT,
AST and LDH into the circulation. As shown in Figure 1,
APAP elevated the plasma ALT, AST and LDH by 64%,
135% and 292% above control, respectively (all differ-
ences at p<0.001 vs. control). Regardless of the enzyme
tested, all the test compounds demonstrated a protective
effect against these elevations. For example, the plasma
ALT rose to only 24%, 35% and 21% in the presence of
HYTAU, TAU and NAC, respectively (all differences at
p<0.05 vs. control) (Figure 1). Likewise, the elevation in
plasma AST were limited to 23% (p<0.05) by HYTAU, to
39% by TAU (p<0.01) and to 34% (p<0.01) by NAC
above control (Figure 2); and that of LDH to 78% by
HYTAU, to 103% by TAU and to 60% by NAC (all differ-
ences at p<0.001 vs. APAP) (Figure 3).
The effect of APAP, alone and in combination with a
sulfur-containing compound, on the liver GSH, GSSG and
GSH/GSSG ratio
As seen in Figure 2, a toxic dose of APAP lowered the
liver GSH by 76% of the control value (p<0.001). While
a pretreatment with HYTAU reversed this effect (1%
above control), one with TAU (6% decrease) or NAC
(only 2% decrease) resulted in significant attenuation.
APAP also lowered the liver GSSG content by 47% of
the control value (p<0.001). This decrease was limited
to 35% (p<0.01) by HYTAU, to 22% (p<0.05) by TAU,
and to 31% (P<0.01) by NAC relative to control (Figure
3). As a result of the greater lowering of the GSH con-
tent relative to that of GSSG by APAP, the correspond-
ing GSH/GSSG ratio was found to be significantly
below the control value (by 54%, p<0.001) (Figure 4).
All the pretreatment compounds were able to raise the
ratio to a value above control, with HYTAU (74%
increase, p<0.001) being much more effective than either
Figure 1 Attenuation by NAC, HYTAU and TAU of APAP-induced elevation of the plasma ALT, AST and LDH activities. Differences were
significant at *p<0.05, **p<0.01 and ***p<0.001 vs. control; and at °p<0.05, °°p<0.01 and °°°p<0.001 vs. APAP. Each bar represents the mean ± S.
E.M. for n = 6.
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TAU (21% increase, p<0.05) or NAC (46% increase,
p<0.001) (Figure 4).
The effect of APAP, alone and in combination with a
sulfur-containing compound, on the plasma GSH, GSSG
and GSH/GSSG ratio
A 39% (p<0.01) reduction in plasma GSH was observed
following a treatment with a toxic dose of APAP. This
reduction amounted to only 19% after a pretreatment
with HTAU (p<0.05) and to only 7% in the presence of
NAC, but was still high (by 28%, p<0.01) in the presence
of TAU compared to the control value (Figure 2). APAP
lowered the plasma GSSG by 25% of the control value
(p<0.05); with the change being affected by a sulfur-con-
taining compound to different extents (22% decrease,
p<0.05, with HYTAU; 2% decrease with TAU; 14%
decrease with NAC) (Figure 3). APAP lowered the
plasma GSH/GSSG ratio by 19% of the control value
(p<0.05). The value of this ratio was increased to above
control by HYTAU (by 3%) and NAC (by 4%) but
Figure 2 Attenuation by NAC, HYTAU and TAU of APAP-induced depletion of the plasma and liver GSH. Differences were significant at
*p<0.05, **p<0.01 and ***p< 0.001 vs. control; and at °p<0.05, °°p<0.01 and °°°p<0.001 vs. APAP. Each bar represents the mean ± S.E.M. for n = 6.
Figure 3 Attenuation by NAC, HYTAU and TAU of APAP-induced depletion of the plasma and liver GSSG. Differences were significant at
*p<0.05 and **p<0.01 vs. control; and at °p<0.05, °°p<0.01 and °°°p<0.001 vs. APAP. Each bar represents the mean ± S.E.M. for n = 6.
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remained below control (by 26%, p<0.01) in the pre-
sence of TAU (Figure 4).
The effect of APAP, alone and in combination with a
sulfur-containing compound, on the liver activities of GR,
GST and GCS
As shown in Figures 5, 6, 7, a toxic dose of APAP
exerted a lowering effect on the hepatic activities of
GR, GST and GCS. In the case of GR, the activity was
reduced by 23% (p<0.05) of the control value (Figure
5). However, this effect was virtually reversed by
HYTAU (only 1% decrease) and effectively attenuated
by TAU (only 8% decrease) and NAC (only 12%
decrease). From the results presented in Figure 6, it
can be seen that APAP lowered the liver GST activity
by 70% of the control value (p<0.001), and that this
Figure 4 Attenuation by NAC, HYTAU and TAU of APAP-induced lowering of the plasma and liver GSH/GSSG ratio. Differences were
significant at *p<0.05, **p<0.01 and ***p<0.001 vs. control; and at °p<0.05, °°p<0.01 and °°°p<0.001 vs. APAP. Each bar represents the mean ± S.
E.M. for n = 6.
Figure 5 Attenuation by NAC, HYTAU and TAU of APAP-induced reduction in plasma and liver GR activity. Differences were significant
at *p<0.05 and **p<0.01 vs. control; and at °p<0.05 and °°p<0.01 vs. APAP. Each bar represents the mean ± S.E.M. for n = 6.
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effect was effectively reduced by HYTAU (only 12%
decrease), TAU (only 31% decrease, p<0.01) and NAC
(only 28% decrease, p<0.01). Similarly, while APAP
lowered the liver GCS activity by 24% of the control
value (p<0.05), a pretreatment with either HYTAU
(only 7% decrease) or TAU (only 12% decrease) led to
significant attenuation and one with NAC (1.5% above
control) to complete reversal of the APAP effect
(Figure 7).
The effect of APAP, alone and in combination with a
sulfur-containing compound, on the plasma activities of
GR, GST and GCS
The results summarized in Figure 5, 6, 7 indicate that
a toxic dose of APAP lowered the plasma activities of
GR, GST and GCS, respectively, and that all the test
compounds offered different degrees of protection
against such losses. Thus, while a treatment with
APAP reduced the GR activity by ~34% of control
Figure 6 Attenuation by NAC, HYTAU and TAU of APAP-induced reduction in plasma and liver GST activity. Differences were significant
at *p<0.05, **p<0.01 and ***p< 0.001 vs. control; and at °°°p<0.001 vs. APAP. Each bar represents the mean ± S.E.M. for n = 6.
Figure 7 Attenuation by NAC, HYTAU and TAU of APAP-induced reduction in plasma and liver GCS activity. Differences were significant
at *p<0.05 vs. control; and at °p<0.05 and °°p<0.01 vs. APAP. Each bar represents the mean ± S.E.M. for n = 6.
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(p<0.01), a combined treatment with HYTAU (only 8%
loss), TAU (~20% loss, p<0.05) or NAC (22% loss,
p<0.05) led to a significant attenuation when compared
to control (Figure 5). Similarly, while APAP lowered
the plasma GST activity by 61% of control (p<0.001), a
pretreatment with HYTAU (5% loss), TAU (26% loss,
p<0.01) or NAC (34% loss, p<0.01) reduced the effect
of APAP to different extents (Figure 6). In terms of
the GCS activity, there was an insignificant (10%)
decrease after a treatment with APAP, and either
reduction of the effect after a co-treatment with
HYTAU (3% loss) or TAU (7% loss) or a reversal of
the effect (2% raise) after a co-treatment with NAC
(Figure 7).
The effect of APAP, alone and in combination with a
sulfur-containing compound, on the liver and plasma
MDA
From the results presented in Figure 8, it is evident that
APAP promoted LPO by increasing the levels of MDA
both in the liver (134%) and plasma (by 217%) above
control values (p<0.001 for both). The same Figure also
indicates that a pretreatment with HYTAU (12%
increase), TAU (22% increase, p<0.05) or NAC (16%
increase, p<0.05) was effective in counteracting the
altering action of APAP on the liver MDA (p<0.001 vs.
APAP). Likewise, the increase in the plasma MDA
induced by APAP was reduced to 32% by NAC
(p<0.01), to 36% by HYTAU (p<0.01), and to 90% by
TAU (p<0.001) relative to the control value (Figure 8).
Discussion
This study has compared NAC, TAU and HYTAU for
their ability to protect the liver against the oxidative
stress and hepatocellular injury that follows a suprather-
apeutic dose of APAP. All the experiments were con-
ducted with male Sprague-Dawley rats since this animal
model was previously found appropriate for assessing
the role of TAU in preventing hepatic injury by a toxic
dose of APAP [29]. The dose (2.4 mmol/kg) and the
route and timing of the administration of the various
test compounds were based on the results of earlier stu-
dies from this laboratory and which found TAU to exhi-
bit antioxidant properties capable of protecting
erythrocytes against the deleterious effects of oxidative
stress, including LPO, GSH depletion, and enzyme inac-
tivation [30,31]. Protection by a sulfur-containing com-
pound against hepatotoxicity by APAP was gauged on
the basis of the increases in the plasma activities of
enzymes serving as indices of hepatic injury (i.e., ALT,
AST, LDH) and on the extent of oxidative stress,
inferred from the levels of MDA, GSH and GSSH and
the activities of enzymes relevant to GSH redox cycling
(GR), conjugating transfer to appropriate substrates
(GST) and synthesis (GCS) in both the plasma and liver.
NAC is regarded as the antidote of choice for treating
APAP overdoses. The most accepted explanation for the
protective actions of this N-substituted amino acid deri-
vative is that it serves as a source of L-cysteine for GSH
synthesis and, hence, it can facilitate the detoxification
of NAPQI before this reactive metabolite can initiate
Figure 8 Attenuation by NAC, HYTAU and TAU of APAP-induced increase in plasma and liver MDA. Differences were significant at
*p<0.05, **p<0.01 and ***p< 0.001 vs. control; and at °°p<0.01 and °°°p<0.001 vs. APAP. Each bar represents the mean ± S.E.M. for n = 6.
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hepatic injury [17,38]. However, NAC is only protective
as long as a viable cysteine-driven synthesis of GSH is
operative [25] since it is ineffective when the hepatic
store of GSH is artificially depleted by a treatment with
buthionine sulfoximine, an inhibitor of GCS [18,39]. A
more recent proposal, put forth to account for the pro-
tective mechanism of NAC in APAP overdoses, is that
this cysteine analog acts as a scavenger of ROS and
OONO- and that it supports mitochondrial energy
metabolism [40].
Since TAU, an end product of the metabolism of
cysteine through the cysteinesulfinic acid pathway [41],
is a poor scavenger of oxygen-derived free radicals [42],
it antioxidant effects on the liver are probably exerted
indirectly, possibly by preventing LPO [29], by suppres-
sing ROS formation [43,44] or by protecting mechan-
isms that replenish the intracellular stores of GSH
during oxidative disturbances [45,46]. Alternatively,
TAU may attenuate oxidative stress and, thereby, pre-
vent the loss of GSH, by increasing the activities of anti-
oxidant enzymes such as CAT and GPX to scavenge
cytotoxic ROS [47,48].
HYTAU, the sulfinate analog of TAU and the immedi-
ate biological precursor of TAU, has been compared to
TAU as a scavenger of free radicals, H2O2 and HClO in
cell-free ROS generating systems [26,43] and in plasma
free hemocytes [49]. While HYTAU was able to sca-
venge HClO and HO•, it was unreactive towards the
O2
-• and H2O2[26,43,49]. In contrast, TAU was found to
be a poor scavenger of free radicals and H2O2 and to
readily bind to HClO [26]. Still, other studies have
found further differences between these sulfur com-
pounds, including protection by HYTAU, but not by
TAU, against ONOO--related cell injury possibly
because of the oxidability of its sulfinic group to sulfo-
nate by ONOO-[50]. Moreover, the addition of HYTAU
to a sperm preparation was reported to decrease H2O2-
induce ROS formation and to protect against H2O2-
induced DNA damage [51].
In spite of the differences in structural features and in
intrinsic antioxidant characteristics among the three test
compounds evaluated here, they were all found to offer
significant protection against the hepatotoxic effects of
APAP. However, and except for a few isolated instances,
HYTAU and NAC were generally more protective than
TAU. In addition to contributing to the maintenance of
the membrane integrity of hepatocytes, as inferred from
the lower plasma activities of ALT, AST and LDH, ser-
ving as markers of liver damage, these compounds were
also able to markedly reduce the production of MDA,
an indicator of LPO, and to return the intracellular
levels of GSH to values that were equal to (HYTAU) or
just below (NAC, TAU) the control value. Likewise, all
three test compounds were able to attenuate the
lowering action of APAP on the liver GSSG content by
about one-half (TAU) or better (HYTAU, NAC) but not
to the point of preventing the reversal of the hepatic
GSH/GSSG ratio seen with APPA alone, namely from
below to above the control value. Surprisingly, HYTAU
showed a greater ability to elevate the GSH/GSSG ratio
than NAC even though HYTAU is not a precursor of
GSH which is the case of NAC. On the other hand, a
toxic dose of APAP lowered the hepatic activities of
those enzymes involved either in de novo synthesis of
GSH (i.e., GCS), GSH nucleophilic addition to substrates
with electrophilic functional groups (i.e., GST) or in the
redox cycling of GSH and GSSG (i.e., GR). The present
results indicate that although APAP can negatively affect
the activities of these hepatic enzymes, the extent of its
effects will vary according to the enzyme, in all likeli-
hood because of the known differences in sensitivity of
GSH-related enzymes to a given oxidizing agent [52].
Thus, APAP had a profound effect on GST (70% reduc-
tion) and a rather moderate one (~24% reduction) on
both GCS and GR. Within a narrow range of potencies,
HYTAU was somewhat more effective than NAC in
curtailing the changes in GR and GST caused by APAP;
and NAC was the only treatment compound to raise the
GCS activity to baseline values. In contrast, TAU was
equipotent to HYTAU in preserving the GR activity,
about equipotent to NAC in preserving the GST activity,
and weaker than either HYTAU or NAC in protecting
the GCS activity.
GR is an enzyme that plays a critical role in oxidative
stress by APAP since a decrease in its activity will lead
to interruption of the cycling between GSSG and GSH
and, thus, to GSH shortage. Although the impairment of
GR activity by APAP is not well understood, at least two
hypothesis have been put forth to explain this occur-
rence, one invoking a direct action of ROS or toxic alde-
hydes and another ascribing the effect to the conjugate
between NAPQI and GSH that forms in the presence of
GST [13]. The noted difference in inhibitory action by
APAP on GSH-related enzymes is in close agreement
with the results of in vitro experiments with cultured
human cells and in which the exposure of enzymes ger-
mane to GSH utilization and redox cycling to H2O2 or
to different organic peroxides revealed marked differ-
ences in susceptibility to inactivation. Indeed, while glu-
tathione peroxidase (GPX), a SH-requiring enzyme
participating in peroxide elimination, was found to be
highly susceptibility to inhibition by peroxides, GR and
GST remained unaltered [52,53]. Moreover, the acute
administration of a single 375 mg/kg of APAP to mice
was reported to decrease the total GSH content, GSH/
GSSG ratio and activities of selenium and non-sele-
nium-dependent GPX activities, and to increase O2
-•
production. Due to the inhibition of GPX, this study
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concluded that hepatic cell injury was the result of an
increase in the steady state level of H2O2 and hydroper-
oxides [54]. While this suggestion implies that oxidative
stress is determining factor of GSH depletion, there is
also evidence to support the opposite order of events,
namely that ROS production follows the depletion of
GSH [55].
Protection by NAC, HYTAU and TAU against APAP-
induced liver injury is also a reflection of their ability to
prevent the loss of GCS activity to a toxic dose of
APAP, an enzyme that plays a crucial role in protecting
the liver against hepatotoxic compounds by regulating
the de novo synthesis of GSH. The importance of this
role for GCS has been experimentally verified through
the use g-GCS knockdown rats [56] or a specific inhibi-
tor of GCS activity such as buthionine sulfoximine [18]
and in which hepatotoxicity by APAP was more exten-
sive than in normal or uninhibited animals. Conversely,
transgenic mice with enhanced GCS activity were found
resistant to APAP-induced liver injury [57].
Regarding the alterations in biochemical parameters
due to a high dose of APAP and detected in plasma
samples, it is apparent that while they all closely parallel
the changes observed in the liver, they were, in all but
one instance, of a lesser magnitude. The only notable
exception was the level of MDA which was almost 2-
fold greater in the plasma than in the liver. In terms of
the test compounds, and in common with the findings
for the liver samples, HYTAU was again somewhat
more potent than NAC and TAU was again the least
potent in attenuating APAP-induced biochemical
alterations.
In conclusion, the present study has determined that
when NAC, HYTAU or TAU are administered to rats
in equal doses and as a pretreatment to a toxic dose of
APAP, they can equally attenuate the hepatocellular
damage, oxidative stress, and alterations in GSH redox
cycling, utilization and transfer caused by APAP.
Although HYTAU and TAU do not play a role in the
biosynthesis of hepatic of GSH, as NAC does, they are,
unexpectedly, equipotent to NAC in maintaining a nor-
mal store of GSH and a normal GSH/GSSH ratio in the
liver. The protective actions of the tests compounds,
based on the magnitude of their actions on the liver
and plasma alterations brought about by APAP
decreased in the approximate order HYTAU>NAC>-
TAU. Also, the present results clearly suggest that the
antioxidant actions demonstrated by these sulfur-con-
taining compounds in an animal model of APAP toxi-
city would not have been predicted from the results for
antioxidant activity gathered using cell-free in vitro sys-
tems generating free radicals or including a peroxide
compound.
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